Compare Cadila Healthcare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC PHARMA CADILA HEALTHCARE/
ALEMBIC PHARMA
 
P/E (TTM) x 14.8 15.6 95.1% View Chart
P/BV x 2.9 3.6 80.6% View Chart
Dividend Yield % 1.4 1.1 133.3%  

Financials

 CADILA HEALTHCARE   ALEMBIC PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ALEMBIC PHARMA
Mar-19
CADILA HEALTHCARE/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs558664 84.0%   
Low Rs362412 87.7%   
Sales per share (Unadj.) Rs116.3208.7 55.7%  
Earnings per share (Unadj.) Rs17.931.0 57.6%  
Cash flow per share (Unadj.) Rs23.137.1 62.3%  
Dividends per share (Unadj.) Rs3.505.50 63.6%  
Dividend yield (eoy) %0.81.0 74.5%  
Book value per share (Unadj.) Rs85.4144.2 59.2%  
Shares outstanding (eoy) m1,023.74188.52 543.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.6 153.3%   
Avg P/E ratio x25.717.4 148.2%  
P/CF ratio (eoy) x19.914.5 137.0%  
Price / Book Value ratio x5.43.7 144.2%  
Dividend payout %19.617.7 110.4%   
Avg Mkt Cap Rs m470,664101,461 463.9%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,5457,467 248.4%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,04939,347 302.6%  
Other income Rs m1,13294 1,206.8%   
Total revenues Rs m120,18139,441 304.7%   
Gross profit Rs m28,4758,736 326.0%  
Depreciation Rs m5,3881,152 467.6%   
Interest Rs m911184 494.8%   
Profit before tax Rs m23,3087,493 311.1%   
Minority Interest Rs m62811 5,814.8%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,568 360.1%   
Profit after tax Rs m18,2925,844 313.0%  
Gross profit margin %23.922.2 107.7%  
Effective tax rate %24.220.9 115.8%   
Net profit margin %15.414.9 103.5%  
BALANCE SHEET DATA
Current assets Rs m82,00519,577 418.9%   
Current liabilities Rs m60,72014,896 407.6%   
Net working cap to sales %17.911.9 150.3%  
Current ratio x1.41.3 102.8%  
Inventory Days Days7390 81.5%  
Debtors Days Days9845 216.8%  
Net fixed assets Rs m83,70327,097 308.9%   
Share capital Rs m1,024377 271.6%   
"Free" reserves Rs m86,42126,811 322.3%   
Net worth Rs m87,44527,188 321.6%   
Long term debt Rs m25,5514,993 511.7%   
Total assets Rs m180,65347,778 378.1%  
Interest coverage x26.641.7 63.8%   
Debt to equity ratio x0.30.2 159.1%  
Sales to assets ratio x0.70.8 80.0%   
Return on assets %10.612.6 84.3%  
Return on equity %20.921.5 97.3%  
Return on capital %22.023.6 93.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68319,453 219.4%   
Fx outflow Rs m11,2426,065 185.4%   
Net fx Rs m31,44113,388 234.8%   
CASH FLOW
From Operations Rs m9,1938,120 113.2%  
From Investments Rs m-9,737-7,556 128.9%  
From Financial Activity Rs m515590 87.2%  
Net Cashflow Rs m-291,153 -2.5%  

Share Holding

Indian Promoters % 74.8 74.1 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.9 286.2%  
FIIs % 5.9 9.1 64.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 13.9 79.1%  
Shareholders   44,069 49,328 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 20, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - VENUS REMEDIES COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS